Statement Of Cash Flows [Abstract]

Biotest AG - Filing #6464577

Concept 2024-01-01 to
2024-12-31
2023-01-01 to
2023-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Adjustments for finance income (cost)
339,000,000 EUR
400,000,000 EUR
Cash flows from (used in) operations before changes in working capital
901,000,000 EUR
2,017,000,000 EUR
Increase (decrease) in working capital
2,000,000 EUR
1,685,000,000 EUR
Adjustments for depreciation and amortisation expense and impairment loss (reversal of impairment loss) recognised in profit or loss
406,000,000 EUR
359,000,000 EUR
Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss, trade and other receivables
79,000,000 EUR
EUR
Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss, inventories
377,000,000 EUR
477,000,000 EUR
Adjustments for gain (loss) on disposals, property, plant and equipment
1,000,000 EUR
EUR
Adjustments for undistributed profits of investments accounted for using equity method
140,000,000 EUR
24,000,000 EUR
Income taxes paid, classified as operating activities
87,000,000 EUR
117,000,000 EUR
Cash flows from (used in) investing activities [abstract]
Purchase of property, plant and equipment, intangible assets other than goodwill, investment property and other non-current assets
287,000,000 EUR
334,000,000 EUR
Purchase of financial instruments, classified as investing activities
17,000,000 EUR
24,000,000 EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.